IDEXX says Q2 2026 revenue rise is driven by double-digit growth in companion animal diagnostics recurring sales
IDXX•Margins, instrument placements and outlook
Premium instrument placements totaled 5,265 units, including 1,602 inVue Dx analyzers; instrument revenue fell 20% organically on a tougher comparison.
Comparable operating margin rose 110 basis points to 35%, aided by recurring revenue mix, productivity, and favorable product costs; EPS was $4.27.
Full-year guidance increased to revenue of $4.7 billion-$4.75 billion, organic growth of 8.5%-9.7%, and EPS of $14.69-$14.94.
Q2 revenue and recurring diagnostics growth
IDEXX posted Q2 2026 revenue growth of about 10% reported, driven by 10.3% organic growth in CAG Diagnostics recurring revenue.
Performance reflected higher testing volumes despite a 1.3% decline in U.S. same-store clinical visits; net price improvement ran about 4% globally.
